The PARP inhibitor AZD2881, also known as olaparib or LynparzaTM, showed promise in mouse models of breast cancer [18] and quickly moved into clinical trials, showing anti-tumour activity in BRCA-mutated cancers, even in phase I studies [19]. Here, PARP1 is linked to neoplasm.